FR3050380B1 - Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. - Google Patents

Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. Download PDF

Info

Publication number
FR3050380B1
FR3050380B1 FR1653502A FR1653502A FR3050380B1 FR 3050380 B1 FR3050380 B1 FR 3050380B1 FR 1653502 A FR1653502 A FR 1653502A FR 1653502 A FR1653502 A FR 1653502A FR 3050380 B1 FR3050380 B1 FR 3050380B1
Authority
FR
France
Prior art keywords
blocker
beta
antihypertensor
nsaid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1653502A
Other languages
English (en)
Other versions
FR3050380A1 (fr
Inventor
Gilles Fonknechten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1653502A priority Critical patent/FR3050380B1/fr
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Priority to EA201892354A priority patent/EA201892354A1/ru
Priority to MA044728A priority patent/MA44728A/fr
Priority to PCT/FR2017/050929 priority patent/WO2017182754A1/fr
Priority to TNP/2018/000344A priority patent/TN2018000344A1/en
Priority to SG10202009894PA priority patent/SG10202009894PA/en
Priority to RU2018140193A priority patent/RU2756320C2/ru
Priority to UAA201811111A priority patent/UA125511C2/uk
Priority to BR112018070968A priority patent/BR112018070968A2/pt
Priority to CN201780023915.6A priority patent/CN109069438A/zh
Priority to KR1020187033434A priority patent/KR102267965B1/ko
Priority to GEAP201714923A priority patent/GEP20217310B/en
Priority to EP17722115.7A priority patent/EP3445342A1/fr
Priority to SG11201808848SA priority patent/SG11201808848SA/en
Publication of FR3050380A1 publication Critical patent/FR3050380A1/fr
Priority to PH12018502155A priority patent/PH12018502155A1/en
Application granted granted Critical
Publication of FR3050380B1 publication Critical patent/FR3050380B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Abstract

Compositions pharmaceutiques fixe comprenant un bétabloquant, le bisoprolol, un agent antihypertenseur, le périndopril, et, un 3ème agent thérapeutique et, utilisation de ladite composition pour le traitement et la prévention de maladies cardiovasculaires et plus particulièrement l'hypertension artérielle et la maladie coronaire stable.
FR1653502A 2016-04-20 2016-04-20 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. Active FR3050380B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR1653502A FR3050380B1 (fr) 2016-04-20 2016-04-20 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.
KR1020187033434A KR102267965B1 (ko) 2016-04-20 2017-04-19 베타 차단제, 전환 효소 억제제 및 항고혈압제 또는 nsaid를 포함하는 약학적 조성물
PCT/FR2017/050929 WO2017182754A1 (fr) 2016-04-20 2017-04-19 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains
TNP/2018/000344A TN2018000344A1 (en) 2016-04-20 2017-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
SG10202009894PA SG10202009894PA (en) 2016-04-20 2017-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
RU2018140193A RU2756320C2 (ru) 2016-04-20 2017-04-19 Фармацевтическая композиция, содержащая бета-блокатор, ингибитор превращающего фермента и гипотензивное средство или нпвс
UAA201811111A UA125511C2 (uk) 2016-04-20 2017-04-19 Фармацевтична композиція, що містить бета-блокатор, інгібітор перетворення ферменту та протигіпертонічний засіб або нпзп
BR112018070968A BR112018070968A2 (pt) 2016-04-20 2017-04-19 composição farmacêutica compreendendo beta-bloqueador, inibidor da enzima conversora e anti-hipertensivo ou ains
EA201892354A EA201892354A1 (ru) 2016-04-20 2017-04-19 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ β-БЛОКАТОР, ИНГИБИТОР ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА И ГИПОТЕНЗИВНОЕ СРЕДСТВО ИЛИ НПВС
MA044728A MA44728A (fr) 2016-04-20 2017-04-19 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains
GEAP201714923A GEP20217310B (en) 2016-04-20 2017-04-19 Pharmaceutical composition comprising beta blocker, converting enzyme inhibitor and antihypertensive or nsaid
EP17722115.7A EP3445342A1 (fr) 2016-04-20 2017-04-19 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains
SG11201808848SA SG11201808848SA (en) 2016-04-20 2017-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
CN201780023915.6A CN109069438A (zh) 2016-04-20 2017-04-19 包含β阻滞剂、转化酶抑制剂和抗高血压药或NSAID的药物组合物
PH12018502155A PH12018502155A1 (en) 2016-04-20 2018-10-05 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1653502 2016-04-20
FR1653502A FR3050380B1 (fr) 2016-04-20 2016-04-20 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.

Publications (2)

Publication Number Publication Date
FR3050380A1 FR3050380A1 (fr) 2017-10-27
FR3050380B1 true FR3050380B1 (fr) 2020-07-10

Family

ID=56943614

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1653502A Active FR3050380B1 (fr) 2016-04-20 2016-04-20 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.

Country Status (14)

Country Link
EP (1) EP3445342A1 (fr)
KR (1) KR102267965B1 (fr)
CN (1) CN109069438A (fr)
BR (1) BR112018070968A2 (fr)
EA (1) EA201892354A1 (fr)
FR (1) FR3050380B1 (fr)
GE (1) GEP20217310B (fr)
MA (1) MA44728A (fr)
PH (1) PH12018502155A1 (fr)
RU (1) RU2756320C2 (fr)
SG (2) SG11201808848SA (fr)
TN (1) TN2018000344A1 (fr)
UA (1) UA125511C2 (fr)
WO (1) WO2017182754A1 (fr)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
FR2503155A2 (fr) 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620709B1 (fr) 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2807431B1 (fr) 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
FR2827860B1 (fr) 2001-07-24 2004-12-10 Servier Lab Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
AR036187A1 (es) 2001-07-24 2004-08-18 Adir Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
DK1333026T3 (da) 2002-01-30 2007-10-22 Servier Lab Fremgangsmåde til fremstilling af perindopril med höj renhed og nyttige mellemforbindelser til syntesen
FR2838648B1 (fr) 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
US7521566B2 (en) 2003-02-28 2009-04-21 Les Laboratoires Servier Process for preparation of perindopril and salts thereof
ES2250846T3 (es) 2003-02-28 2006-04-16 Les Laboratoires Servier Nuevo procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables.
DE60300581T2 (de) 2003-03-12 2006-01-19 Les Laboratoires Servier Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmba- ren Salzen
ES2256689T3 (es) 2003-06-30 2006-07-16 Les Laboratoires Servier Nuevo procedimiento de sintesis del perindopril y de sus sales farmaceuticamente aceptables.
DK1362864T3 (da) 2003-06-30 2007-09-17 Servier Lab Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
CA2531279A1 (fr) * 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Traitement et prevention d'accidents cardiovasculaires
PT1367063E (pt) 2003-07-31 2006-12-29 Servier Lab Novo processo de síntese do perindopril e dos seus sais farmacêuticamente aceitáveis
DK1367062T3 (da) 2003-07-31 2007-01-02 Servier Lab Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
ATE306496T1 (de) 2003-08-29 2005-10-15 Servier Lab Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
DK1380590T3 (da) 2003-08-29 2007-01-08 Servier Lab Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
ATE310012T1 (de) 2003-08-29 2005-12-15 Servier Lab Verfahren für die synthese von perindopril und seiner pharmazeutisch annehmbaren salzen
ES2282586T3 (es) 2003-11-19 2007-10-16 Les Laboratoires Servier Procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables.
EP1422236B1 (fr) 2003-11-19 2007-02-14 Les Laboratoires Servier Procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
ATE386745T1 (de) 2003-12-10 2008-03-15 Servier Lab Verfahren für die synthese von perindopril und seiner pharmazeutisch annehmbaren salzen
SI21800A (sl) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
FR2894825B1 (fr) 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2897866B1 (fr) 2006-02-28 2008-04-18 Servier Lab Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2897865B1 (fr) 2006-02-28 2008-04-18 Servier Lab Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN101024082A (zh) * 2007-04-06 2007-08-29 张士东 一种全面预防和治疗心脑血管疾病复方药及其应用
WO2009157018A2 (fr) 2008-06-24 2009-12-30 Matrix Laboratories Ltd Nouvelles formes polymorphes de perindopril (l)-arginine et processus de préparation correspondants
HU230877B1 (hu) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
US9789187B2 (en) * 2009-02-11 2017-10-17 Cadila Pharmaceuticals Limited Stable pharmaceutical composition for atherosclerosis
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
FR2985511B1 (fr) 2012-01-05 2014-01-03 Servier Lab Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
RU2756320C2 (ru) 2021-09-29
SG11201808848SA (en) 2018-11-29
EA201892354A1 (ru) 2019-04-30
EP3445342A1 (fr) 2019-02-27
KR102267965B1 (ko) 2021-06-21
TN2018000344A1 (en) 2020-06-15
MA44728A (fr) 2019-02-27
RU2018140193A3 (fr) 2020-06-03
SG10202009894PA (en) 2020-11-27
WO2017182754A1 (fr) 2017-10-26
KR20180132911A (ko) 2018-12-12
RU2018140193A (ru) 2020-05-20
UA125511C2 (uk) 2022-04-13
PH12018502155A1 (en) 2019-07-15
FR3050380A1 (fr) 2017-10-27
CN109069438A (zh) 2018-12-21
BR112018070968A2 (pt) 2019-01-29
GEP20217310B (en) 2021-11-10

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA44851B1 (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
MA29316B1 (fr) Derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
BRPI0510024A (pt) compostos e composições como modulares de ppar
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA50406B1 (fr) Inhibiteurs pyrazole de magl
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
CL2023002393A1 (es) Anticuerpos anti-cd30l y usos de estos
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
FR3050380B1 (fr) Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.
MA38699B1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA40915B1 (fr) Composition pharmaceutique comprenant le bisoprolol et le périndopril
FR3040303B1 (fr) Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
MA44769B1 (fr) Formulations destinées à une utilisation dans le traitement ou la prévention de maladies urologiques
WO2019244014A3 (fr) Nouvelle utilisation d'inhibiteurs de monoamine oxydase de type b

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20171027

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8